# Lecture 2: Hematopoiesis and Hemostasis

## Anatomy and Physiology II

---

## Learning Objectives

By the end of this lecture, students will be able to:

1. Define hematopoiesis and identify the sites where it occurs
2. Describe the lineage of blood cell development from pluripotent stem cells
3. Explain the regulation of erythropoiesis, including the role of erythropoietin
4. Describe the three stages of hemostasis
5. Explain the intrinsic and extrinsic pathways of the coagulation cascade
6. Discuss the mechanisms that limit clot formation and promote fibrinolysis
7. Identify common disorders of hemostasis

---

## Lecture Content

### I. Hematopoiesis — Overview

Hematopoiesis is the production of all formed elements of the blood. Every blood cell in the body originates from a single common precursor: the pluripotent hematopoietic stem cell, also called the hemocytoblast. The location of hematopoiesis shifts during development. In the embryo, blood cells are first produced in the yolk sac during the initial weeks of gestation. As the fetus develops, production shifts to the liver and spleen from the second trimester onward. After birth and throughout the remainder of life, the red bone marrow assumes this responsibility. In adults, red marrow is found primarily in the axial skeleton (the sternum, ribs, vertebrae, pelvis, and skull) and in the proximal epiphyses of the humerus and femur. Yellow bone marrow, which consists largely of fatty tissue, can revert to red marrow and resume blood cell production if demand for new cells increases significantly.

#### Hematopoietic Stem Cell Lineages

The pluripotent hematopoietic stem cell gives rise to two major progenitor lines. The **myeloid stem cell** produces erythrocytes (via the proerythroblast pathway), platelets (via megakaryocytes), all three types of granulocytes (neutrophils, eosinophils, and basophils), and monocytes. The **lymphoid stem cell** produces T lymphocytes, which mature in the thymus, B lymphocytes, which mature in the bone marrow, and natural killer (NK) cells. A crucial feature of hematopoietic stem cells is their capacity for self-renewal, which maintains the stem cell pool throughout life. The differentiation of stem cells along specific lineages is driven by colony-stimulating factors (CSFs), interleukins, and other cytokines that act as growth and differentiation signals.

<image>A comprehensive hematopoietic lineage tree diagram. At the top, a single pluripotent hematopoietic stem cell branches into a myeloid stem cell (left) and a lymphoid stem cell (right). The myeloid branch shows differentiation pathways to: proerythroblast leading to reticulocyte then erythrocyte; megakaryoblast leading to megakaryocyte then platelets; myeloblast leading to neutrophil, eosinophil, and basophil; and monoblast leading to monocyte then macrophage. The lymphoid branch shows pathways to: T lymphocyte progenitor maturing in the thymus to become T cells; B lymphocyte maturing in bone marrow; and NK cell. Key growth factors (EPO, TPO, CSFs, interleukins) are labeled at their points of action along each pathway.</image>

### II. Erythropoiesis

Erythropoiesis is the process by which new red blood cells are produced. It takes approximately 15 days from the moment a stem cell commits to the erythroid lineage until a mature erythrocyte is released, and it occurs exclusively in the red bone marrow.

#### Stages of Erythropoiesis

The process begins with the **proerythroblast**, a committed progenitor cell that is large and still possesses a nucleus. This cell matures into the **early (basophilic) erythroblast**, which begins synthesizing hemoglobin; the abundance of ribosomes at this stage gives the cell its basophilic staining character. As hemoglobin accumulates, the cell transitions into the **polychromatic erythroblast**, which displays mixed staining properties. The next stage, the **late (orthochromatic) erythroblast**, features a condensing nucleus and a nearly full complement of hemoglobin. The nucleus is then ejected, producing a **reticulocyte** that retains a few residual ribosomes and organelles. Reticulocytes are released into the bloodstream and typically comprise 1 to 2% of circulating red blood cells, maturing into fully functional **erythrocytes** within 1 to 2 days.

#### Regulation of Erythropoiesis

The primary stimulus for red blood cell production is tissue hypoxia, meaning low oxygen levels in the tissues. When cells detect inadequate oxygenation, the kidneys respond by producing **erythropoietin (EPO)**, a hormone secreted mainly by peritubular interstitial cells in the renal cortex, with a small additional contribution from the liver. EPO acts on the bone marrow to accelerate the maturation and release of erythrocyte precursors, particularly proerythroblasts and reticulocytes.

This system operates through a classic negative feedback loop. When hypoxia is detected by kidney cells, EPO is released into the blood. The bone marrow responds by ramping up red blood cell production, which increases the number of circulating erythrocytes and improves tissue oxygenation. Once oxygen levels return to normal, EPO production decreases. Conditions that trigger increased EPO release include hemorrhage, excessive red blood cell destruction, decreased hemoglobin content, and reduced oxygen availability (as occurs at high altitude or in lung disease).

Erythropoiesis also depends on adequate nutritional inputs. Iron is essential for heme synthesis and is absorbed in the duodenum, then stored as ferritin and hemosiderin. Vitamin B12 and folic acid are required for DNA synthesis during the rapid cell divisions of erythropoiesis. Additional cofactors including copper, zinc, amino acids, and vitamin B6 play supporting roles in hemoglobin synthesis.

#### Erythrocyte Destruction and Recycling

Old or damaged red blood cells are recognized and removed by macrophages residing in the spleen, liver, and bone marrow. The hemoglobin within these cells is systematically dismantled. The globin chains are hydrolyzed into their constituent amino acids, which are recycled for use in new protein synthesis. The heme groups are split into iron and biliverdin. The iron is bound to the transport protein transferrin and carried through the blood to the bone marrow for reuse or stored as ferritin. Biliverdin is converted to bilirubin, which travels to the liver bound to albumin. The liver conjugates bilirubin and excretes it in bile. In the intestine, bacteria convert bilirubin to urobilinogen and then to stercobilin, which gives feces their characteristic brown color. A small fraction of urobilinogen is reabsorbed into the bloodstream and excreted by the kidneys as urobilin, accounting for the yellow color of urine.

<image>A diagram illustrating erythrocyte life cycle and hemoglobin recycling. Panel A: The erythropoiesis feedback loop — showing kidneys detecting hypoxia, releasing EPO, stimulating bone marrow, increasing RBC production, and restoring oxygen levels with a negative feedback arrow. Panel B: The hemoglobin recycling pathway — showing an aged RBC being engulfed by a macrophage in the spleen, hemoglobin breakdown into globin (recycled amino acids), iron (stored as ferritin or carried by transferrin back to bone marrow), and bilirubin (transported to liver, excreted in bile, converted to stercobilin in feces and urobilin in urine). Each step is clearly labeled with arrows showing the flow.</image>

### III. Thrombopoiesis

Thrombopoiesis is the production of platelets from megakaryocytes in the bone marrow. Megakaryocytes are remarkable cells that undergo a process called endomitosis, in which the nucleus divides repeatedly without the cell itself splitting, resulting in a single enormous polyploid cell. The cytoplasm of this giant cell then fragments, shedding approximately 2,000 to 3,000 platelets per megakaryocyte. The process is regulated by thrombopoietin (TPO), a hormone produced mainly by the liver that stimulates megakaryocyte proliferation and maturation. Platelets circulate for approximately 5 to 10 days before aged platelets are removed by macrophages in the spleen.

### IV. Hemostasis

Hemostasis is the rapid, localized process that stops bleeding when a blood vessel is injured. It unfolds in three overlapping stages: vascular spasm, platelet plug formation, and coagulation.

#### Stage 1: Vascular Spasm

The first response to vascular injury is an immediate constriction of the damaged blood vessel as the smooth muscle in its wall contracts. This vascular spasm is triggered by direct injury to the smooth muscle, by chemicals released from endothelial cells and platelets (such as thromboxane A2 and serotonin), and by reflexes initiated by local pain receptors. By narrowing the vessel lumen, the spasm reduces blood flow and limits blood loss. This mechanism is most effective in smaller vessels and can persist for minutes to hours.

#### Stage 2: Platelet Plug Formation

Within seconds of injury, platelets begin accumulating at the damaged site. The process unfolds in three steps. First, **platelet adhesion** occurs as exposed collagen fibers in the subendothelial layer attract circulating platelets. Von Willebrand factor (vWF) acts as a molecular bridge, linking the collagen to glycoprotein Ib receptors on the platelet surface. Second, **platelet activation** takes place: the adhered platelets change shape, extending pseudopods that make them sticky, and they degranulate, releasing ADP, thromboxane A2, serotonin, calcium, and platelet-derived growth factor (PDGF). Third, **platelet aggregation** occurs as ADP and thromboxane A2 recruit additional platelets to the site, while fibrinogen molecules bridge platelets together via GPIIb/IIIa receptors. This positive feedback cycle rapidly builds a platelet plug that is effective at sealing small breaks in vessel walls. For larger injuries, however, the coagulation cascade is also required.

#### Stage 3: Coagulation (Blood Clotting)

Coagulation is a cascade of enzymatic reactions that ultimately converts soluble fibrinogen into a mesh of insoluble fibrin threads, reinforcing the platelet plug. The cascade involves roughly 13 clotting factors (numbered I through XIII), most of which are produced by the liver. Many of these factors, particularly Factors II, VII, IX, and X, require vitamin K for their synthesis. Most clotting factors circulate as inactive zymogens that are activated sequentially.

Two converging pathways initiate coagulation. The **extrinsic pathway** (tissue factor pathway) is the faster of the two, operating within seconds. It is triggered when tissue factor (TF, also known as Factor III) is released from damaged cells outside the blood vessel. Tissue factor activates Factor VII, and the resulting TF-VIIa complex activates Factor X. The **intrinsic pathway** (contact activation pathway) is slower, taking minutes, and is triggered when Factor XII contacts exposed collagen or activated platelets. Factor XII activates Factor XI, which activates Factor IX, and the Factor IXa-VIIIa complex then activates Factor X.

Both pathways converge at Factor Xa, which marks the beginning of the **common pathway**. Factor Xa combines with Factor Va to form the prothrombinase complex, which converts prothrombin (Factor II) into thrombin. Thrombin then converts fibrinogen (Factor I) into fibrin monomers, which spontaneously polymerize into a fibrin mesh. Factor XIII, activated by thrombin, cross-links the fibrin strands to create a stable, durable clot. Thrombin also provides powerful positive feedback by activating Factors V, VIII, and XI, as well as recruiting additional platelets.

<image>A flowchart of the coagulation cascade. Panel A: The extrinsic pathway on the left — tissue factor plus Factor VII leading to Factor Xa. Panel B: The intrinsic pathway on the right — Factor XII activation by collagen leading through Factors XI, IX, and VIII to Factor Xa. Panel C: The common pathway at the bottom — Factor Xa plus Factor Va forming prothrombinase, converting prothrombin to thrombin, thrombin converting fibrinogen to fibrin, and Factor XIIIa cross-linking fibrin. Positive feedback loops from thrombin back to Factors V, VIII, and XI are shown with dashed arrows. Calcium ion requirements are noted at each relevant step.</image>

### V. Clot Retraction and Fibrinolysis

#### Clot Retraction

Once a clot has formed, the platelets trapped within it contract using their actin and myosin filaments. This clot retraction pulls the wound edges closer together, squeezes out serum (plasma minus clotting proteins), and promotes wound healing by compacting the clot into a tighter, more effective seal.

#### Fibrinolysis

After healing is underway, the clot must be removed. During clot formation, an inactive enzyme called plasminogen becomes trapped within the fibrin mesh. Endothelial cells release tissue plasminogen activator (tPA), which converts plasminogen into its active form, plasmin. Plasmin then digests the fibrin strands, gradually dissolving the clot. This mechanism has important clinical applications: tPA is administered as a thrombolytic drug to dissolve clots in patients experiencing heart attacks or strokes.

### VI. Anticoagulant Mechanisms — Limiting Clot Formation

Because unchecked clotting would be catastrophic, the body deploys several mechanisms to confine clot formation to the site of injury. **Antithrombin III** is a circulating protein that inactivates thrombin and other clotting factors, and its activity is greatly enhanced by heparin, which is produced by basophils and mast cells. **Protein C** and **Protein S** work together to inactivate Factors Va and VIIIa. **Tissue factor pathway inhibitor (TFPI)** blocks the TF-VIIa complex of the extrinsic pathway. Intact endothelial cells release **prostacyclin (PGI2)**, which inhibits platelet adhesion and aggregation, and **nitric oxide (NO)**, which acts as both a vasodilator and a platelet inhibitor. Finally, the smooth, intact endothelial surface itself physically prevents platelet adhesion, ensuring that clotting is triggered only where the vessel lining has been disrupted.

### VII. Clinical Correlations

Several disorders disrupt the balance of hemostasis. **Hemophilia A**, an X-linked recessive condition, results from a deficiency of Factor VIII and leads to prolonged bleeding. **Hemophilia B** (Christmas disease) involves a deficiency of Factor IX. **Von Willebrand disease**, the most common inherited bleeding disorder, results from a deficiency or dysfunction of von Willebrand factor, which is essential for platelet adhesion. **Disseminated intravascular coagulation (DIC)** is a life-threatening condition in which widespread clotting consumes clotting factors and platelets, paradoxically leading to uncontrolled bleeding. **Deep vein thrombosis (DVT)** involves clot formation in the deep veins, usually of the legs, and carries the risk of pulmonary embolism if a piece of the clot dislodges and travels to the lungs. **Thrombocytopenia**, a low platelet count, increases bleeding risk. **Vitamin K deficiency** impairs the synthesis of Factors II, VII, IX, and X, leading to increased bleeding. Clinically, **warfarin** is an anticoagulant drug that inhibits vitamin K-dependent clotting factor synthesis, while **aspirin** reduces platelet aggregation by inhibiting thromboxane A2 production.

---